Department of Justice Declines to Intervene in Lawsuit against Gilead Sciences Regarding Ranexa(R)

FOSTER CITY, Calif., Dec 16, 2010 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that, after conducting an investigation, the United States Department of Justice ("DOJ") has notified the United States District Court for the Northern District of California "of its decision not to intervene" in a False Claims Act lawsuit filed by a former employee of CV Therapeutics, Inc. regarding the promotion of Ranexa(R) (ranolazine extended release tablets). Gilead acquired CV Therapeutics in April 2009.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

SOURCE: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Nathan Kaiser, 650-522-1853 (Media)